STRATEGIC LEADER KIRAN MAZUMDAR SHAW

SUBMITTED BY: JIGESH CHAUDHARY(G1003) DRASHTI DHOLAKIA(G1007) VANDANA KASHYAP(G1011) ANKITA MANKANI(G1018) DRASHTI MEHTA(G1020) SHREYAS PATEL(G1029) RAHUL DOSHI(NR 10121)

DR.KIRAN MAZUMDAR SHAW

Dr. Kiran Mazumdar-Shaw has entered the elite ranks of the Indian business world as India's richest woman. Born on 23 March, 1953, she is the Chairman & Managing Director of Biocon Ltd. She did her schooling from Bangalore and graduated in Zoology from Bangalore University in 1973, after which she moved on to Ballarat University in Melbourne, Australia. She became India's first woman Brew Master and started off as a trainee brewer in Carlton & United Beverages in 1974, following which she worked in various positions in Kolkata and Vadodara.

She collaborated with Biocon Biochemicals Limited, Ireland, to found Biocon India in 1978. Initially, she faced many problems, but she was not the one to give up. Her firm has grown to be the biggest biopharmaceutical firm in India today. Though her business interests keep her occupied, she has found time to write a book titled 'Ale and Arty'. She tied the knot with John Shaw, in 1998, who was working as the managing director of Madura Coats. After their marriage, John Shaw quit Madura Coat and joined Biocon.

A very active social activist, she has been involved in various projects like the Bangalore Agenda Task Force (BATF). She was awarded the MV Memorial Award, given in honour of the great engineer and visionary Sir M Vishwesharaiah. Apart from this, she was awarded the Wharton Infosys Business Transformation Award in 2006, the Padma Bhushan in 2005, the Lifetime Achievement Award from the Indian Chamber of Commerce in 2005, the Ernst & Young Entrepreneur of the Year Award in Healthcare & Life Sciences Category in 2002 besides the Padma Shri in 1989.

AWARDS Kiran Mazumdar-Shaw has received several awards on behalf of Biocon and in her personal capacity as one of India's leading business entrepreneurs. Biocon: 2010

Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio

2009 Biocon among Top 20 Indian companies in Forbes Best Under A Billion list.

Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio

Syngene wins Bio-Excellence Award for outstanding achievement in the Biotech Service Sector at Bangalore Bio

Biocon bags IDMA "Best Patent of the year" award BIOMAb EGFR was voted Bio-Spectrum Asia-Pacific Product of the year, 2008

Biocon wins prestigious BioSingapore Asia Pacific Biotechnology Award for Best Listed Company 2008

Biocon is ranked among the top 20 global biotechnology companies (Source: Med Ad News,

June 2008)

Biocon is the 7th largest biotech employer in the world (Source: Med Ad News, June 2008)

2007 Syngene receives "BioServices Company of the Year", BioSpectrum Awards Biocon's BIOMAb EGFR wins "Product of the Year", BioSpectrum Awards 2006 Best IT User Award in the Pharmaceutical Sector, NASSCOM 2004 India's first and No. 1 biotech company with a global ranking of 16* (Source: Biospectrum July 2004)

Biocon in India's top 5 Life Sciences companies (at close of trade as on July 30, 2004)

Best Reinvention of HR Function Award, Indira Group, Mumbai

Best Employer Of India Award, Hewitt

2003

Bio-Business Award for bio-entrepreneurship, Rabo India

Express Pharma Pulse Award for excellence in the pharmaceutical industry

2001

Biotech Product, Process Development and Commercialisation Award, Department of Biotechnology, Ministry of Science and Technology, Government of India

2000

Technology Pioneer Recognition, World Economic Forum 1985 Export Performance Award, Karnataka State Financial Corporation (KSFC)

National Award for Best Small Industry, Government of India Kiran Mazumdar-Shaw: 2010 Featured on the Forbes list of The Worlds 100 Most Powerful Women. Featured on the Financial Times Top 50 Women in Business list. Named among TIME magazines 100 most influential people in the world. 2009

Honoured with 'Nikkei Asia Prize' for Regional Growth

Honoured with 'Express Pharmaceutical Leadership Summit Award' for Dynamic Entrepreneur

2008

Honorary Degree of Doctor of Science from the Heriot-Watt University, Edinburgh

Honorary Degree of Doctor of Science from the University of Glasgow

2007

Honoured with the, 'Veuve Clicquot Initiative For Economic Development For Asia' award

Honorary Doctor of Technology, University of Abertay, Dundee ( UK )

2005

Padmabhushan Award , one of India's highest civilian honours, from the President of India, Dr. APJ Abdul Kalam

Honorary Degree of Doctor of Science (Honoris Causa) from Indian Institute of Technology, Roorkee The Indian Chamber of Commerce Lifetime Achievement Award

Honorary Doctorate from Manipal Academy of Higher Education (MAHE), in recognition of outstanding achievements in biotechnology and industrial enzymes

Rotary Award for Corporate Citizenship

Business Leader of the Year Award - Biotechnology, Chemtech-Pharma Bio Awards

2004

Honorary Doctorate of Science from Ballarat University, in recognition of pre-eminent contribution to the field of biotechnology

Business Woman Of The Year Award, The Economic Times 2003 Alumni High Achiever Award, Australian Alumni Association

2002

Karnataka Rajyotsava Award for pioneering biotechnology in India, the Government of Karnataka

Best Entrepreneur: Healthcare & Life Sciences Award, Ernst & Young

Sir M. Visvesvaraya Memorial Award for contribution to biotechnology, Federation of Karnataka Chambers of Commerce & Industry (FKCCI)

1999

Woman of the Year Award, International Women's Association, Chennai

1998

Golden Jubilee Felicitation, Mount Carmel College, Bangalore

1989

Padmashri for pioneering biotechnology in India, Government of India 1987 Outstanding Young Person Award, Jaycees India 1983 Best Small Scale Industry in Karnataka Award, Rotary Club, Karnataka

Best Model Employer Award, Rotary Club, Karnataka

Outstanding Contribution Award, AWAKE

1982

Best Woman Entrepreneur Award, National Institute of Marketing Management, India

Mission

To be an integrated biotechnology enterprise of global distinction. Essential to this mission is excellence in: - Intellectual asset creation through discovery, research and development

- State-of-the-art manufacturing capabilities

- Internationally benchmarked quality and regulatory systems

- New medical insight through disease specific clinical research

- Customer relationship through outstanding products and services

- Human resource development through training, mentoring and empowering

- Management of research and business partnerships Strategic Alliances

Research Partnerships/Collaborations Biocon Announces Strategic Collaboration with Mylan to enter the Global Generic Biologics Market

BIOCON - MYLAN: 2009

Biocon Limited announced that it has executed a definitive agreement with Mylan Inc. (Nasdaq: MYL) for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace. Through this partnership, Mylan and Biocon bring together highly complementary capabilities that will significantly advance their efforts to secure a leading position in the emerging generic biologics industry.

About Mylan Inc:

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest and highest quality product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

Biocon Limited and Amylin Pharmaceuticals Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid

Program will Focus on the Potential Treatment of Diabetes

BIOCON - AMYLIN: 2009

Biocon, Limited (NSE: BIOCON) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that they have entered into an exclusive agreement to jointly develop, commercialize

and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylins phybrid technology. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. About Amylin Pharmaceuticals:

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN (pramlintide acetate) injection and BYETTA (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com Syngene and DuPont Crop Protection Forge Alliance Partnership

SYNGENE - DuPONT CROP PROTECTION: 2009

Syngene International, a subsidiary of BIOCON Ltd, Indian biotechnology major, announced its agreement as alliance partner with DuPont Crop Protection. Syngene has been a preferred research service provider to DuPont Crop Protection primarily in the field of discovery chemistry and biology and will now provide integrated research services, through its "one box" model, covering a broad range of R&D technical capabilities to support DuPont's discovery pipeline.

About DuPont:

DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and

construction; communications; and transportation.

SYNGENE- BRISTOL-MYERS SQUIBB: 2009

Syngene International and Bristol-Myers Squibb (BMS) [a global biopharmaceutical company, headquartered in New York], announced the opening of a fully dedicated research and development facility for BMS in Biocon Park, Bangalore. Syngene and BMS entered into this research partnership for developing integrated drug discovery and development capabilities in 2007. Through this partnership, Syngene will provide research and development services for discovery and early drug development to BMS. The dedicated research facility developed by Syngene spreads across an area of 200,000 sq. ft. and has capacity to accommodate over 450 employees. Syngene is the preferred research service provider to BMS for providing drug discovery and development process from initial hit to lead optimization to early pharmaceutical development to clinical nomination in Phase I and Phase II clinical studies.

About BMS:

Bristol-Myers Squibb (BMS), having units worldwide, manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular diseases, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Syngene and Endo Pharma Collaboration to Develop Anti-cancer Novel Therapeutic Molecules

SYNGENE- ENDO PHARMACEUTICALS: 2010

Syngene and Endo Pharmaceuticals, a US-based, specialty healthcare solutions company, has entered into a discovery and development collaboration to develop novel biological therapeutic molecules against cancer. Through this partnership, Syngene and Endo Pharmaceuticals hope to

leverage their synergistic capabilities to develop novel therapeutic molecules for a robust cancer pipeline.

About Endo Pharmaceuticals:

Endo Pharmaceuticals, incorporated in 1997, is a specialty pharmaceutical company engaged in research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children or central precocious puberty (CPP).The company markets its branded pharmaceutical products to physicians for pain management, urology, endocrinology, oncology, neurology, surgery and primary care.

Strategic Co-development ventures Partnership for the co-development of immunoconjugates for targeted immunotherapy of cancers and infectious diseases

BIOCON- IATRICa, 2008

Biocon Limited and IATRICa, Inc. announced a strategic partnership to co-develop an exclusive new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies will co-develop candidate products based upon IATRICas technology platform and Biocons proven expertise in drug development, biologics manufacturing, and clinical research.

About IATRICa Inc.:

IATRICa is a privately held biotechnology company engaged in the discovery and development of novel targeted immunoconjugates for prevention or treatment of cancer and infectious disorders. IATRICa is a start-up company formed in 2007 with technology developed at the Johns Hopkins University, Baltimore, Maryland, USA, and has exclusive licenses to the

immunoconjugate technology invented by Johns Hopkins scientists and company founders, Dr. Atul Bedi and Dr. Rajani Ravi. The company is headquartered in Baltimore, Maryland, USA. Partnership to Discover and Develop Therapeutic Antibodies

BIOCON-VACCINEX: 2004

Biocon and Vaccinex, Inc. have embarked on a broad, strategic partnership to discover and codevelop fully humanized antibodies focused on cancer, inflammation and autoimmune diseases. The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.

Progress: Currently, BVX-20 a monoclonal antibody (intended for use in the treatment of patients with relapsed or chemotherapy resistant follicular B-cell NHL and CD20 positive diffuse large B- cell NHL in combination with chemotherapy) has moved into preclinical stages.

Vaccinex is a privately held biotechnology company headquartered in Rochester, New York engaged in the discovery and development of novel therapeutic antibodies. Partnership to Manufacture and Market Biopharmaceuticals in GCC Countries

BIOCON- NEOPHARMA: 2007

Biocon and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).

This landmark agreement between the two companies heralds the region's first foray to develop and market life saving biopharmaceutical products.

zMarketing Alliances and commercialization

Biocon and Pfizer enter into Global Commercialization Agreement for commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products BIOCON PFIZER: 2010

Biocon Limited and Pfizer entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Biocon will remain responsible for the clinical development, manufacture and supply of these biosimilar Insulin products, as well as for regulatory activities to secure approval for these products in various geographies. This alliance enables Biocon to extend its insulin portfolio to have a worldwide presence. Licensing agreement for G CSF in North America and the European Union & for the commercialisation of ABRAXANE in India BIOCON-ABRAXIS: 2007

Biocon and Abraxis BioScience, Inc. have announced an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union. Under the terms of the agreement, Biocon will receive an upfront licensing fee and, following approval in the licensed territories, royalties from Abraxis BioScience.

In addition, Biocon and Abraxis BioScience Inc., have also announced a licensing agreement for the commercialization of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the terms of the agreement, Biocon will also have the right to market ABRAXANE in Pakistan, Bangladesh, Sri Lanka, United Arab Emirates, Saudi Arabia, Kuwait and certain other Persian Gulf countries. As part of this agreement, Abraxis will receive royalties from Biocon based on net sales of ABRAXANE in these countries.

Progress: Drug Controller General of India (DCGI) approval has been obtained to market ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer. Commercial introduction of ABRAXANE in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Exclusive Marketing License for BIOMAb EGFR for Pakistan

BIOCON-FEROZSONS: 2007

Biocon has granted an exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR in Pakistan. The successful debut made by BIOMAb EGFR in the Indian market since mid-September, 2006, has evinced strong licensing interest for the proprietary cancer drug in the region. Biocon's decision to select Ferozsons Laboratories Limited as its exclusive licensee in Pakistan was based on the leadership position that the company enjoys in Oncology.

Ferozsons Laboratories Limited is the foremost national Oncology company in Pakistan. Collaboration in Research and Research-Education BIOCON-KAROLINSKA INSTITUTE: 2005

Biocon signed a Memorandum of Understanding (MoU) with the Karolinska Institute, Sweden to collaborate in research and research-education initiatives.

The agreement outlines the following areas of collaboration:

- Partnering in product development

- Joint PhD studies at Karolinska Institute

- Joint research programs between Karolinska Institute and Biocon

- Scientific symposia in India sponsored by Biocon in association with Karolinska Institute

Progress

- Joint Ph.D. programs are being conducted.

- In 2006, Madras Diabetes Research Foundation (MDRF) and Karolinska Institute of Sweden organized a diabetes symposium. Biocon was a cosponsor.

Karolinska Institute is Sweden's leading medical university, reputed to be among Europe's best. The institute's reputation for visionary science has afforded it the exceptional honour and responsibility to nominate The Nobel Prize for Medicine and Physiology every year. Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management

BIOCON - ISB: 2009

Biocon Limited, India's pioneering biotechnology company and the Indian School of Business (ISB) have launched the Biocon Cell for Innovation Management (BCIM) to promote innovation

in business. The Cell will be established under the aegis of the Centre for Leadership, Innovation, and Change (CLIC) at the ISB. BCIM at the ISB will help organizations find answers to questions such as the gaps in a company's ability to innovate, assessing the required understanding to manage and mitigate risks associated with innovation and how to produce high value, high quality, strategic innovation at low cost. Biocon is contributing an initial investment of Rs. 1 crore to set up BCIM.

About ISB:

The Indian School of Business is a premier management institution established in 2001. In a short span of seven years, the ISB has successfully pioneered several new trends in management education in India and has established itself as a leading B-school across the world. The ISB has a strong pool of research oriented resident faculty and invites high calibre international faculty from reputed B-schools to teach in its Post Graduate Programme in Management/Executive Education Programmes as well as to participate in collaborative research with the resident faculty. The ISB has academic associations with the Kellogg School of Management, The Wharton School, and the London Business School.

Partnership for Greater Focus in Biotechnology and Biosciences Research

BIOCON- DEAKIN UNIVERSITY: 2007

Biocon signed a Memorandum of Understanding with Deakin University for cooperation in the following areas:

-Establishment of the Deakin Research Institute in Bangalore.

-Joint development of a mammalian cell bio-processing facility at Geelong, Victoria, Australia.

Deakin University, Victoria is Australia's fastest growing university in multi- disciplinary research with greater focus in biotechnology and biosciences research.